Biomea Fusion to be added to NASDAQ Biotechnology Index
Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on irreversible small molecules for genetically defined cancers, has been added to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes NASDAQ-listed companies in the Biotechnology and Pharmaceuticals sectors that meet specific criteria. Biomea’s proprietary FUSION™ discovery platform aims to enhance treatment selection, potentially improving patient outcomes through more selective and durable drug responses.
- Addition to the NASDAQ Biotechnology Index, which can enhance visibility and credibility.
- Focus on irreversible small molecules may offer competitive advantages in cancer treatment.
- None.
REDWOOD CITY, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers, today announced that the company has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Nasdaq selects constituents once annually in December. For more information about the NASDAQ Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Biomea Fusion
Biomea Fusion is a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ discovery platform to advance a pipeline of irreversible treatments against key oncogenic drivers of cancer. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the clinical benefit when treating various cancers.
Contact:
Van Sandwick
Director, Investor Relations & Corporate Development
vsandwick@biomeafusion.com
(650) 460-7759
FAQ
What is Biomea Fusion's stock symbol?
When will Biomea Fusion be added to the NASDAQ Biotechnology Index?
What does Biomea Fusion focus on?
What is the significance of being added to the NASDAQ Biotechnology Index for BMEA?
